Picture a BD team at a mid-cap oncology company in late March, staring at a termsheet that arrived — unsolicited — from a large-cap acquirer. The offer landed on a Tuesday. By Friday, two competing bids were on the table. The asset in question: a Phase 2 solid tumor program with clean biomarker data and a projected peak sales estimate north of $1.5 billion. Six months ago, that asset would have cleared one serious suitor. Today it cleared three, and the auction hadn’t even formally opened. Something had shifted in the dealmaking atmosphere — and it wasn’t just appetite.
The final two weeks of March 2026 produced seven transactions totaling $29 billion across the biopharma sector. That number deserves a moment of context before anyone dismisses it as a seasonal blip or a corrective bounce from a sluggish first quarter. It isn’t either of those. What the March surge actually represents is the visible exhaust of a structural recalibration that began quietly in Q4 2025 — when a handful of large-caps started burning through their pre-positioned BD&L war chests faster than analysts had modeled.
The Q4 2025 activity was dismissed in some quarters as a one-time flush, companies clearing deals before year-end balance sheet snapshots. March proved that interpretation wrong.
The Clock Everyone Is Pretending Not to Watch
The underlying driver here is not macro optimism or a suddenly permissive regulatory environment. It is a patent cliff of unusual severity bearing down on the industry’s largest revenue generators. Pfizer faces meaningful loss of exclusivity pressure across its portfolio through the late 2020s. AbbVie’s Humira, already deep into biosimilar erosion, set the template: a blockbuster that once printed $20 billion annually now competes against more than ten biosimilar entrants. Bristol Myers Squibb has publicly flagged LOE exposure on Revlimid and Opdivo that will require replacement revenue in the $15 billion range by the end of the decade, a figure cited across multiple BMS investor presentations.
When you model what it actually takes to replace $15 billion in revenue organically — through internal R&D pipelines with average phase transition success rates hovering around 10% for Phase 1 assets — the math collapses almost immediately. You cannot build your way out of a cliff this steep. You have to buy your way around it, and the window to do so at rational risk-adjusted NPV is narrow.
That is why seven deals in two weeks is not a coincidence. It is a synchronized response to a deadline that every CFO in the industry has on their internal whiteboard, even if no one announces it during earnings.
The counterintuitive read here — and it matters — is that the sellers are the ones with the structural advantage right now, not the acquirers. Conventional wisdom frames M&A as a buyer’s market when valuations compress and biotech indices underperform. Biotech had a rough stretch through parts of 2024 and 2025. But a compressed valuation environment only benefits acquirers when there is no competitive tension. The moment you have multiple large-caps chasing the same therapeutic whitespace — immuno-oncology combinations, next-generation GLP-1 mechanisms, complement pathway assets — the bid premium logic inverts. Eisai and Biogen’s lecanemab partnership, structured with milestone payments extending well past initial approval, is the kind of deal architecture that gets repriced aggressively when a rival announces a competing Phase 3 readout. That same dynamic is now playing out in real time across half a dozen therapeutic categories simultaneously.
What the Term Sheets Actually Reveal
Look at how the deals in the March cluster are being structured, not just what they cost. The presence of substantial contingent value rights in several transactions signals something specific: acquirers are not fully convinced their own valuation models hold, so they are offloading downstream risk back onto sellers through milestone architecture. This is not unusual in biopharma M&A — CVRs are a standard tool. But the size of the contingent component relative to upfront payment tells you how confident a buyer actually is in the asset’s probability of technical and regulatory success.
When an acquirer fronts 60% of the deal value upfront and CVR-gates the remaining 40% on Phase 3 success and FDA approval, that is a PTRS argument embedded in the contract. The buyer’s own internal model is saying the asset has roughly a coin-flip chance of clearing both hurdles. That is worth knowing if you are a competitor trying to understand whether the acquirer just bought genuine pipeline depth or bought optionality and a press release.
Merck’s acquisition of Prometheus Biosciences in 2023 for $10.8 billion — a deal that valued tulisokibart based largely on Phase 2 data in inflammatory bowel disease — provides the relevant precedent. The premium was enormous relative to the stage of the asset. But Merck was not paying for what Prometheus had proven. It was paying to block competitors from owning a mechanism it needed in its immunology portfolio ahead of Keytruda’s LOE exposure later this decade. Several of the March 2026 deals carry that same fingerprint: the price is not a valuation, it is a preemption fee.
Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, completed in early 2025 for Caplyta’s CNS franchise, demonstrated how rapidly large-caps will move when a differentiated asset with real-world commercial traction appears in an undercrowded payer category. CNS reimbursement is notoriously difficult terrain — payers have historically resisted premium pricing for psychiatric indications. J&J paid the premium anyway, because at peak sales projections in the $3 to $4 billion range for Caplyta, the math still worked inside a neuroscience portfolio that needed revenue velocity.
The Repricing Nobody Has Modeled
Here is what the sell-side consensus on 2026 M&A is missing. The activity everyone is tracking — headline deal counts, aggregate transaction values, premium percentages — is the surface layer. The deeper structural shift is a repricing of what Phase 2 data is worth in a competitive BD environment where large-caps are simultaneously chasing similar therapeutic categories.
When Novo Nordisk and Eli Lilly are both aggressively scouting next-generation obesity and cardiometabolic mechanisms — and both have the balance sheet depth to execute nine-figure or ten-figure deals without blinking — the floor price for any credible GLP-1 adjacent asset with Phase 2 proof of concept moves up structurally. Not deal by deal. Across the category. Every Phase 2 sponsor in that space is now negotiating against an implied reserve price set by whoever gets to the table first. That is a market-wide valuation effect, and it compounds.
The same dynamic is emerging in complement biology, where AstraZeneca’s Ultomiris franchise demonstrated that a differentiated mechanism in rare hematology can sustain premium pricing against biosimilar-adjacent competition. Any sponsor with a Phase 2 complement asset is now pricing their partnering conversation against AstraZeneca’s demonstrated willingness to pay for category extension. According to AstraZeneca’s 2024 annual results, rare disease contributed meaningfully to the company’s double-digit revenue growth — which means the internal BD mandate to protect that franchise through bolt-on acquisition is well-funded and active.
The BD team from the opening scene — the one staring at three competing bids by Friday — understood something instinctively that the market has not yet fully priced. Their asset’s value was not determined by their Phase 2 data alone. It was determined by the convergence of four large-caps all running the same LOE-driven NPV model and arriving at the same therapeutic whitespace at the same time. In that environment, $29 billion across seven deals in two weeks is not a surge.
It is a starting price.
References
- FierceBiotech — “March M&A surge triggers high expectations for 2026” (March 2026)
- Bristol Myers Squibb — Investor Presentation, Loss of Exclusivity Exposure Disclosure (2024–2025)
- AstraZeneca — Annual Results and Revenue Breakdown, Rare Disease Franchise (2024)
- Johnson & Johnson — Press Release, Acquisition of Intra-Cellular Therapies for $14.6 Billion (January 2025)
- Merck — Press Release, Acquisition of Prometheus Biosciences for $10.8 Billion (2023)
- AbbVie — Earnings Transcripts, Humira Biosimilar Erosion and Revenue Impact (2023–2025)
- Biogen and Eisai — Lecanemab Commercial Partnership and Milestone Structure, Investor Disclosures (2023–2024)
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
